853908-49-3

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 5-bromo-2-[(2-nitroethenyl)amino]-, is used as an intermediate in the synthesis of pharmaceuticals for its potential to contribute to the development of new drugs. Its unique functional groups allow for the creation of diverse medicinal compounds with specific therapeutic properties.
Used in Chemical Industry:
In the chemical industry, Benzoic acid, 5-bromo-2-[(2-nitroethenyl)amino]-, serves as a building block for the production of dyes and perfumes. Its structural components can be utilized to create a range of aromatic compounds that impart color and fragrance to various products.
Used in Organic Synthesis:
The presence of the nitroethenylamino group in Benzoic acid, 5-bromo-2-[(2-nitroethenyl)amino]-, makes it a potentially useful reagent for organic synthesis. It can be employed in the preparation of a variety of organic compounds, expanding its applications beyond the pharmaceutical and chemical industries.

InChI:InChI=1/C9H7BrN2O4/c10-6-1-2-8(7(5-6)9(13)14)11-3-4-12(15)16/h1-5,11H,(H,13,14)

Upstream product

• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 74-89-5 methylamine 
• 860439-13-0 2-nitrovinyl-hydroxylamine 
• 74189-16-5 2-amino-5-bromobenzoic acid hydrochloride 
• 75-52-5 nitromethane 

Downstream Products

• 1395145-15-9 2-(4-(8-(2-aminobenzo[d]oxazol-5-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitril 

Relevant academic research and scientific papers

Compound serving as Hippo signal channel inhibitor

The invention provides a compound represented by a formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The compound disclosed by the invention has an inhibiting effecton a Hippo signal channel, and can be used for preparing a Hippo signal channel inhibitor. Meanwhile, cell proliferation can be promoted by inhibiting a Hippo signal channel, regeneration of damagedorgans is facilitated, particularly regeneration of damaged liver tissues can be promoted, and acute liver injury can be effectively repaired. Therefore, the compound provided by the invention can also be used for preparing medicines for treating various diseases related to the Hippo signal channel, such as medicines beneficial to regeneration of damaged organs, particularly medicines beneficial to regeneration of damaged liver tissues, and medicines for repairing acute liver injury. The compound can be used for medication research in the field of organ regeneration.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

JAK P13K/mTOR COMBINATION THERAPY

Provided herein is a combination therapy comprising a JAK kinase inhibitor and a dual PBK/mTOR inhibitor, as well as methods of treating various cancers through the use of such a combination therapy.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to substituted imidazo[4,5-c]quinoline derivatives, the compounds of formula (I), wherein R1 R2, R3, R4, R5, R6 and R7 are as defined in the specification, processes for their preparation, pharmaceutical compositions comprising compounds of formula (I), and their use in the treatment of diseases or disorders mediated by one or more kinases, particularly proliferative diseases or disorders such as cancer. These compounds can also be used in the treatment of inflammatory diseases and angiogenesis related disorders.

SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES

The present invention relates to substituted imidazo[4,5-c]quinoline derivatives of formula (I), wherein R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions comprising compounds of the present invention and their use in the treatment of diseases or disorders mediated by one or more kinases, particularly proliferative diseases or disorders such as cancer. These compounds can also be used in the treatment of inflammation and angiogenesis related disorders.

1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The invention relates to imidazoquinolines of formula (I) for use in the treatment of protein kinase dependent diseases; pharmaceutical preparations comprinsing an imidazoquinoline, especially for the treatment of a pretein kinase dependent disease; novel imidazoquinolines; and a process for the preparation of the novel imidazoquinilines.